Last reviewed · How we verify

Spectrum Pharmaceuticals, Inc — Portfolio Competitive Intelligence Brief

Spectrum Pharmaceuticals, Inc pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
VLI VLI marketed Vinca alkaloid β-tubulin Oncology
SPI-2012 SPI-2012 phase 3 PLK1 inhibitor PLK1 (Polo-like kinase 1) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique Hopitaux De Marseille · 1 shared drug class
  2. Polaryx Therapeutics, Inc. · 1 shared drug class
  3. Universität des Saarlandes · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Spectrum Pharmaceuticals, Inc:

Cite this brief

Drug Landscape (2026). Spectrum Pharmaceuticals, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/spectrum-pharmaceuticals-inc. Accessed 2026-06-10.

Related